Protocol Ledger

NCT04512430 · Phase II · TERMINATED

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Interventional Phase II clinical trial protocol NCT04512430 sponsored by Fundación GECP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-02 Enrollment: 4 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04512430
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)4 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04512430
Protocol FieldVerified Registry Value
NCT IdentifierNCT04512430
Consolidated Lead SponsorFundación GECP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment4 participants (ACTUAL)
Registered Start Date2020-12-02
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04512430
Hospital Research SiteLocationSite Profile
Complejo Hospitalario de NavarraPamplona, SpainOpen Hospital Dossier ->
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI